Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center

Background: Natalizumab (NTZ) and fingolimod (FTY) are second-line disease modifying treatments (DMTs) approved for Relapsing – Remitting Multiple Sclerosis (RRMS). Few studies are available on a direct comparison between NTZ and FTY, based on post-marketing experience, with conflicting results and...

Full description

Bibliographic Details
Main Authors: Marina Boziki, Christos Bakirtzis, Virginia Giantzi, Styliani-Aggeliki Sintila, Stylianos Kallivoulos, Theodora Afrantou, Ioannis Nikolaidis, Panagiotis Ioannidis, Theodoros Karapanayiotides, Ioanna Koutroulou, Dimitrios Parissis, Nikolaos Grigoriadis
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Neurology
Subjects:
relapsing-remitting multiple sclerosis
natalizumab
fingolimod
disease-modifying treatment
annualized relapse rate
highly-active multiple sclerosis
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.699844/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.699844/full

Similar Items